Tirzepatide
Support Weight Loss Medication
The latest breakthrough in weight management. As a novel dual GIP and GLP-1 receptor agonist, Tirzepatide delivers unprecedented results — more effective than any other weight loss medication available.
15–22%
Average Weight Loss
Dual
GIP + GLP-1 Agonist
FDA
Approved
#1
Results vs. Any Medication
Why Tirzepatide is Different
Unlike other GLP-1 medications, Tirzepatide activates two separate hormone receptor pathways — GIP (glucose-dependent insulinotropic polypeptide) AND GLP-1 simultaneously. This dual activation is what makes clinical trials show 15–22% average body weight reduction — results no other approved medication has matched.
Dual Mechanism of Action
- GIP Activation: Enhances insulin secretion, reduces glucagon, supports fat metabolism
- GLP-1 Activation: Slows gastric emptying, reduces appetite, promotes satiety
- Synergistic Effect: Both pathways working together produce superior results versus either alone
- Cardiovascular: Improves heart health markers alongside weight management
"I lost 47 pounds in 6 months with Tirzepatide and Coach Kenya's program. The combination of medical support and behavioral coaching is unlike anything else."
— Program Client
What's Included at I.R.I.S.E.
- 15–22% average weight loss — more than any other weight management medication
- Dual mechanism: targets both GIP and GLP-1 receptors simultaneously
- Improves cardiovascular health while managing diabetes effectively
- FDA approved for both diabetes and weight management
- Weekly injection — convenient, once-per-week dosing
- Physician supervised through Dr. Crystal Broussard, MD (licensed in all 50 states)
- Fully integrated with I.R.I.S.E. behavioral and mindset coaching